Please assess the completion status of the following clinical trial:

Trial Title: A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Eastern Cooperative Oncology Group performance status ≤ 1~* Histologically or cytologically confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that was considered incurable by local therapies~* Eligible for pembrolizumab monotherapy based on the current prescribing information for pembrolizumab (Keytruda 2019)~* Must have had 0 to 2 prior therapies for R/M HNSCC~* At least 1 measurable lesion (which has not been previously irradiated) according to Response Evaluation Criteria in Solid Tumors version 1.1~* For stage 1 only: Must have had at least 1 other lesion that could be biopsied and willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion~* For stage 1 only: Must have been willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion~* Adequate organ function defined by the following laboratory parameters:~  * Absolute neutrophil count ≥ 1.5 × 10\^9/liter (L)~ * Platelet count ≥ 100 × 10\^9/L~ * Hemoglobin level ≥ 9.0 grams/deciliter (dL)~ * A serum creatinine level \< 1.5 milligrams/dL, or~ * Estimated creatinine clearance value ≥ 60 milliliters/minute (as determined by the Cockcroft-Gault method) for participants with creatinine levels \> 1.5 × institutional upper limit of normal (ULN)~ * Total bilirubin level ≤ 1.5 × ULN (exception: participants with Gilbert's Syndrome may have a bilirubin level \> 1.5 × ULN)~ * Aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase and alanine aminotransferase/serum pyruvic transaminase levels ≤ 2.5 × ULN or ≤ 5 × ULN in participants with liver metastases~* International normalized ratio or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless participant was receiving anticoagulant therapy in which case PT or aPTT must have been within therapeutic range of intended use of anticoagulants~Exclusion Criteria~* Previously treated with 3 or more systemic regimens given for recurrent and/or metastatic disease~* Received anticancer treatment, major surgery, or any investigational drug within 30 days or 5 half-lives, whichever is shorter, before the start of study intervention~* Received radiation therapy within 14 days before the start of study intervention, including, in addition (if necessary), the timeframe for resolution of any actual or anticipated toxicities from such radiation; Palliative radiation is allowed if \> 7 days and any toxicity is ≤ Grade 1~* Previous treatment with a PI3K, PD-1 or programmed cell death ligand 1 inhibitor~* Have received organ or allogenic bone marrow or peripheral blood stem cell transplant~* History of drug-induced colitis or drug-induced pneumonitis; history or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; tuberculosis treatment within 2 years prior to the start of study intervention; chronic liver disease or veno-occlusive disease/sinusoidal obstruction syndrome~* Active cytomegalovirus or Epstein-Barr virus infection; history of or known human immunodeficiency virus infection~* Ongoing treatment with chronic immunosuppressants or systemic steroids or treatment for systemic bacterial, fungal, or viral infection~* Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening~* Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A. No prior use within 2 weeks before the start of study intervention Received a live or live attenuated vaccine within 6 weeks of first dose of duvelisib~* Unable to receive prophylactic treatment for pneumocystis, HSV, or VZV at screening~* Any active gastrointestinal dysfunction interfering with the participant's ability to be administered oral medications~* Known active central nervous system metastases and/or carcinomatous meningitis~* QT interval \> 500 milliseconds (except for participants with a right or left bundle branch block)~* New York Heart Association Class III or IV congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duvelisib + Pembrolizumab (Type: EXPERIMENTAL): Stage 1: Duvelisib twice daily (BID) for 1 week followed by combination therapy with duvelisib BID + pembrolizumab every 3 weeks (q3w) (Cycle 1 was 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib; subsequent cycles were 3 weeks).~Stage 2: Duvelisib BID + pembrolizumab q3w in 3-week cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues